1.01BMarket Cap
LossP/E TTM
EyePoint Pharmaceuticals Inc
Key Figures
12.450Open
12.498High
1.47MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.77%Turnover Ratio
12.470Prev. Close
12.060Low
13.63MTurnover
LossP/E Static
3.30P/B
0.00%Div Yield TTM
-83.47%ROA
19.11052wk High
1.13Volume Ratio
-130.87MNet Profit
82.83MShares
-3.5053EPS TTM
1.74Beta
-102.71%ROE
6.85052wk Low
3.51%Amplitude
24.14%Gross Margin
1.01BMarket Cap
-2.07Reward/Risk
4.20%Risk Rate
Currency: USD Updated: 2026-07-24 Key Insights
EyePoint Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 69 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 40.50.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
EyePoint Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
EyePoint Pharmaceuticals Inc Highlights
StrengthsRisks
EyePoint Pharmaceuticals Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
EyePoint Pharmaceuticals Inc
EYPT
14
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
EyePoint Pharmaceuticals Inc Info
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
Ticker SymbolEYPT
CompanyEyePoint Pharmaceuticals Inc
CEODuker (Jay S)
Websitehttps://eyepointpharma.com/
Shareholders
FAQs
What is the current price of EyePoint Pharmaceuticals Inc (EYPT)?
The current price of EyePoint Pharmaceuticals Inc (EYPT) is 12.19.
What is the symbol of EyePoint Pharmaceuticals Inc?
The ticker symbol of EyePoint Pharmaceuticals Inc is EYPT.
What is the 52-week high of EyePoint Pharmaceuticals Inc?
The 52-week high of EyePoint Pharmaceuticals Inc is 19.11.
What is the 52-week low of EyePoint Pharmaceuticals Inc?
The 52-week low of EyePoint Pharmaceuticals Inc is 6.85.
What is the market capitalization of EyePoint Pharmaceuticals Inc?
The market capitalization of EyePoint Pharmaceuticals Inc is 1.02B.
Is EyePoint Pharmaceuticals Inc (EYPT) currently rated as Buy, Hold, or Sell?
According to analysts, EyePoint Pharmaceuticals Inc (EYPT) has an overall rating of Buy, with a price target of 41.08.
What is the Earnings Per Share (EPS TTM) of EyePoint Pharmaceuticals Inc (EYPT)?
The Earnings Per Share (EPS TTM) of EyePoint Pharmaceuticals Inc (EYPT) is -3.17.
